Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week Low - Time to Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $11.43 and last traded at $11.65, with a volume of 251118 shares changing hands. The stock had previously closed at $11.60.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on BCAX shares. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an "overweight" rating and a $35.00 target price on the stock. HC Wainwright upped their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday. Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a "buy" rating and a $48.00 target price on the stock. Finally, TD Cowen began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $43.75.

Bicara Therapeutics Stock Down 1.8 %

The stock's 50 day simple moving average is $16.56.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. purchased a new position in Bicara Therapeutics during the 3rd quarter worth $177,169,000. FMR LLC purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $57,913,000. Braidwell LP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $42,219,000. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $30,329,000. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.